Project Grant HT94252410150
Award Date
3/1/24
Completion Date
2/28/27
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319.00 to the University of Pittsburgh to conduct research on "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER." The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its expertise in...
This $846,182 Project Grant award to the University of Pittsburgh was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER" with a performance period from Aug 1, 2024 to Jul 31, 2027. As a major research university, the University of Pittsburgh will leverage its extensive...
The University of Pittsburgh was awarded a $712,770 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year grant will fund research into the role of RUNX1 rearrangements in triple-negative breast cancer progression and immune evasion. Through September 2025, the University will investigate medical solutions for aggressive breast cancers that lack estrogen receptors, progesterone receptors, and excess HER2...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This $520,259 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research at Carnegie Mellon University to develop a liquid biopsy-based approach for predicting pathological complete response in breast cancer patients. The project aims to leverage extracellular vesicles and advanced sequencing techniques to enable ultrasensitive detection of breast cancer-specific genetic mutations. As a...
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The U.S. Department of the Army Medical Command awarded a $718,858 Project Grant to the University of Texas MD Anderson Cancer Center on February 15, 2025. The grant supports the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" research project, which aims to investigate innovative approaches to cancer prevention, diagnosis, and treatment. This grant is funded under the Military Medical Research and Development (CFDA...
This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...